This test is New York DOH approved.
This is a qualitative screening test; clot lysis only occurs in specimens with severe factor XIII deficiency (less than 1 percent of normal activity). Severe deficiency may be inherited or acquired (typically due to a factor XIII antibody). If clot lysis occurs in the initial testing, then Factor XIII 1:1 Mix will be added where the test is repeated using a 1:1 mix of patient plasma and pooled normal plasma to distinguish between FXIII deficiency and a FXIII inhibitor. Additional charges apply.
False-positive results (lysis) can be caused by heparin (therapy with unfractionated or low molecular weight heparin or contamination from a line), decreased or abnormal fibrinogen, increased fibrinolysis (inherited or acquired fibrinolytic disorders), fibrinolytic drugs, or other factors that affect clot structure or stability.
85291; if reflexed, add additional 85291